SINOVAC Receives Nasdaq Delisting Notice and Plans to Appeal

Written by Emily J. Thompson, Senior Investment Analyst

Source: Businesswire

Updated: Nov 18 2025

0mins

Source: Businesswire

Delisting Determination: Sinovac Biotech received a delisting determination from Nasdaq due to non-compliance with Listing Rule 5250(c)(1) for failing to file its 2024 Annual Report on time, with potential suspension set for November 21, 2025.
Independent Auditor Engagement: The company has engaged UHY LLP as its new independent registered public accounting firm to assist in filing the overdue report and plans to appeal the delisting decision to the Nasdaq Hearing Panel.
Compliance Timeline: Sinovac has until November 19, 2025, to request a hearing, which would temporarily stay the suspension of its securities for 15 days, while it works to regain compliance.
Company Overview: Sinovac is a leading biopharmaceutical company in China, known for its vaccine development and commercialization, including COVID-19 and other infectious disease vaccines, and is actively pursuing global market opportunities.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free